메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

Berlin Heals Announces Publication of Two-Year Clinical Out…

Study shows sustained improvements in heart failure symptoms and function following long-term C-MIC therapy ZUG, Switzerland, July 16, 2025 -- Berlin Heals, a pioneer in bioelectric medicine for the treatment of heart failure, is pleased to announce the publication of a new peer-reviewed study titled "Two-year outcomes of a cardiac microcurrent device in chronic heart failure: A first-in-human pilot study" in the ESC Heart Failure journal. The study presents the long-term follow-up of patients enrolled in the initial pilot trial of the Cardiac Microcurrent I
- 김갑성 기자
- 2025-07-16 15:00
JETRO and METI Hold First-ever "Global Healthcare Challenge,"…

[ 메디채널 김갑성 기자 ] - AI Medical Service Inc. from Japan Wins Gold Prize - TOKYO, July 16, 2025 -- During the "Health and Well-being" theme week at the Expo 2025 Osaka, Kansai, the Japan External Trade Organization (JETRO) and Japan's Ministry of Economy, Trade and Industry (METI) jointly hosted an international symposium on healthcare and a pitch competition for healthcare startups from around the world, titled the "Global Healthcare Challenge" (GHeC), at the Grand Prince Hotel Osaka Bay on June 25 (Wednesday) and 26 (Thursday), 2025. The event was designed to help J
- 김갑성 기자
- 2025-07-16 14:00
Senhwa Biosciences announces first patient dosed in NC…

TAIPEI and SAN DIEGO, July 16, 2025 -- Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced that its new drug Pidnarulex (CX-5461) has been selected by the U.S. National Cancer Institute (NCI) as part of a five-year cancer research program. The first patient in the monotherapy clinical trial for advanced solid tumors has been successfully enrolled at the NIH Clinical Center in Bethesda, Maryland, USA. The NCI will fund the full cost of the
- 김갑성 기자
- 2025-07-16 10:32
Medley Expands Operations in the Philippines to Accelerate…

MANILA, Philippines, July 16, 2025 -- Medley (TSE: 4480), a leading Japan-based healthcare technology group, has announced the relocation and expansion of its operational functions in the Philippines to help accelerate the company's global business growth. The new office, located at 32nd Street corner 3rd Avenue, Bonifacio Global City (BGC), Taguig City, offers a sleek, modern space for the company's fast-growing team. It will serve as a key operational hub for Medley's global business and underscores the company's continued commitment to international expansion. Remaining in
- 김갑성 기자
- 2025-07-16 10:17
Fujitsu and Acer Medical trial AI service that assesses future…

TOKYO, July 16, 2025 -- Fujitsu Limited and Acer Medical Inc., a provider of AI-powered medical imaging and preventative medicine, today announced a collaborative agreement to develop "aiGait" powered by Uvance, a solution that leverages Fujitsu's advanced skeleton recognition AI technology to detect gait pattern abnormalities, and provide gait quantization to healthcare professionals to support the early diagnosis of dementia and Parkinson's disease. The technology is part of "Fujitsu Kozuchi for Vision" from the Fujitsu Uvance offering "AI Technologies and Solutions
- 김갑성 기자
- 2025-07-16 10:04
Akeso Announces First Patient Enrolled in the Phase III Trial（…

HONG KONG, July 16, 2025 -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the first patient has been successfully enrolled in the registration Phase III clinical trial (AK112-312/HARMONi-GI6) of ivonescimab in first-line treatment for advanced metastatic colorectal cancer (mCRC). This randomized, controlled, multi-center Phase III clinical trial for first-line treatment of mCRC is one of the company's key initiatives to address the significant unmet clinical need worldwide with ivonescimab. Colorectal cancer remains the third mo
- 김갑성 기자
- 2025-07-16 09:47
ArkBio's Ziresovir Included into Pediatric RSV Drug Priority List by…

SHANGHAI, July 16, 2025 -- In the newly released "Paediatric drug optimization for respiratory syncytial virus (PADO-RSV) meeting report" by Global Accelerator for Paediatric formulations (GAP-f), the World Health Organization (WHO) host network, ziresovir (10mg) has been included in the PADO-RSV priority list. Ziresovir, developed by Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio"), is the first and only RSV antiviral drug to be included in the list. This is the first time WHO has included an anti-RSV drug developed from China in the paediatric drug optimizati
- 김갑성 기자
- 2025-07-16 09:00
PHASE Scientific Expands INDICAID® Respiratory Portfolio with Excl…

FebriDx® is a first-in-class rapid test that differentiates between bacterial and non-bacterial respiratory infections, offering significant potential to address critical unmet needs in patient care by enabling more informed antibiotic use and aiding in the reduction of antimicrobial resistance. Introduction of FebriDx will enhance PHASE Scientific's INDICAID® portfolio and strengthen its leadership in point-of-care respiratory diagnostics. Partnership underscores PHASE Scientific's proven commercial execution in the U.S. market with its extensive nationwide clinical net
- 김갑성 기자
- 2025-07-16 08:54
디바믹스, AI 및 분자동역학 플랫폼 통해 대사질환 신약 개발 돌파구 마련

[ 메디채널 김갑성 기자 ] 쑤저우, 중국 2025년 7월 15일 -- 인공지능(AI) 기반 신약 개발의 선구자인 디바믹스(Divamics)가 첨단 AI 및 분자동역학(molecular dynamics, MD) 플랫폼을 통해 대사 질환 치료제 발전에 핵심적인 역할을 하고 있다고 밝혔다. 이 강력한 플랫폼은 최근 비만 치료를 위한 새로운 이중 작용체(AMY3R/CTR 수용체 작용제)인 BGM1812 설계를 지원했고, 이는 '의약화학 저널(Journal of Medicinal Chemistry)' 2025년 7월호에 발표됐다. 이러한 성과는 파트너사의 신약 개발 파이프라인을 지속적으로 가속화할 수 있도록 지원해 온 디바믹스의 역량을 입증하는 사례다. 협업적 신약 개발에서 AI 기반 효율성 및 정밀도 디바믹스의 플랫폼은 펩타이드-수용체 간 상호작용을 정밀하게 최적화함으로써, BGM1812의 수용체 결합력을 크게 향상시키는 데 핵심적인 역할을 했다. 전임상 연구에서는 BGM1812가 시험관 내(in vitro) 효능이 50% 향상되었고, 생체 내(in vivo) 실험에서도 유의미한 체중 감소와 대사 지표 개선이라는 뛰어난 치료 효
- 김갑성 기자
- 2025-07-16 00:27
XTEND Secures $30M Extension to Complete $70M Series B to Sc…

[ 메디채널 김갑성 기자 ] Aliya Capital Partners and Protego Ventures Co-Lead Strategic Series B Round alongside participating investors: Len Blavatnik's Claltech, Union-Tech Ventures & Chartered Group, as XTEND's AI Robotic Technology Proves Itself in Global Conflicts and the Company Opens Its New U.S. Headquarters in Tampa, Florida TAMPA, Fla., July 15, 2025 -- XTEND, a leader in AI-powered tactical autonomous robotic systems, today announced that [ 메디채널 김갑성 기자 ] Aliya Capital Partners and Protego Ventures have co-led a strategic $30M extension to its $70M Series B funding round, joini
- 김갑성 기자
- 2025-07-15 22:09

이전

31 32 33 34 35 36 37 38 39 40

많이 본 기사

최근기사

2025-08-21_THU

Angelalign Technology Denies Patent Infringement and Vows Vigorous Defense 05:04

2025-08-20_WED

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 08월 21일 06시 40분